Cytis AG Corporate Brochure

We take your innovation further.

The best way to predict the future is to invent it.Alan Kay

The development of innovative medicines has been impacting an ever-growing number of patients in western countries over the last ten years.

However, territories such as the Middle East, Central Europe or even Africa, only benefit from these advances much later on.

Indeed, an innovative compound launched in Europe or the United States, will only appear in the Middle East 5 to 7 years after becoming available in Europe. There are various reasons for this:– Priority being given to the country of origin– Geographic distance or cultural remoteness

Awareness of how to gain access to innovative treatments has also grown in these markets, at the level of supervisory authorities as well as practising doctors and patients - patients who benefit from information that moves faster than ever before.

Cytis AG has set itself the ambitious mission of providing for the needs of such patients and their families, while at the same time contributing to the geographic expansion of innovative businesses, whether this is in the biopharmaceutical, medical equipment or diagnostics field.

Saudi Arabia 28.2 23,200 570Kuwait 2.6 39,300 490Qatar 1.1 80,900 1,283Bahrain 0.8 32,100 1,000United Arab Emirates 4.6 37,300 625Oman 3.3 24,000 390Lebanon 4.0 11,300 584Gulf States 44.6 26,167 584

Turkey 71.9 12,900 592Iran 65.9 10,600 677Egypt 81.7 5,500 279Middle East 1 219.5 9,455 501

Jordan 6.2 4,900 650Yemen 23.0 2,300 88Syria 19.7 4,500 110Armenia 2.0 4,900 270Azerbaijan 8.2 7,700 193Georgia 4.6 4,700 318Middle East 2 63.7 4,184 185

Middle East 328 10,705 451

Europe (27) 499 28,213 3,050USA 304 45,800 6,350

Sources: World Fact Book (2007) & United Nations (2005)

Population GDP Health expensesper capita per capita

2007 (M) 2007 (USD) 2005 (USD)

Saudi Arabia

Kuwait

Qatar

Bahrain

UAE

Oman

Yemen

SyriaIran

Jordan

Lebanon

Egypt

Turkey

Armenia AzerbaijanGeorgia

Iraq

Developing the market.

Patients

Specialized Doctors

Key Account Managers

Local DistributorsCytis AGLaboratory

All the countries of the Middle East have cultural, economic and political features in common.

Each of these countries does however abide by its own specific rules in regulatory and commercial terms; this leads to them being approached individually, by choosing the best local importer/distributor on a country-by-country basis.

The quality of the partnership between your business, the local partner and Cytis, will be the key success factor for your product in this region.

Continuously striving to succeed.

�Product information

�Potential local partner evaluation

�Marketing plan approach

�Evaluation per country

�Local distributor selection (Cytis)

�Country selection (Company and Cytis)

�Agreement: Company and Cytis partnership

�Agreement: Distributor and Company

�Marketing plan finalization

Evaluate Select Commit

The preliminary steps of this approach will be to plan, organise, assign each partner’s role and determine its level of commitment.

�Regulatory strategy

�Name patient basis potential

�Selection of key account manager

�Recruitement

�Medico-marketing training

�Target to key account

�Marketing plan implementation

�Local key opinion leaders

�Logistical aspects

�Administrative aspect

�Financial

�Quarterly reporting

Operate Manage Export and Follow

Cytis AGInnovationszentrumGewerbestrasse 14Postfach 539CH 4123 AllschwilSwitzerland

+41 61 481 88 11 Phone+41 61 481 88 12 Faxwww.cytis.ch